ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Zeria Pharmaceutical Co., Ltd. ?
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 7.64% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 8.64% signifying low profitability per unit of shareholders funds
2
Positive results in Dec 25
- DEBT-EQUITY RATIO (HY) Lowest at 17.44 %
- INTEREST COVERAGE RATIO(Q) Highest at 5,527.14
- RAW MATERIAL COST(Y) Fallen by 0.12% (YoY)
3
With ROCE of 11.39%, it has a very attractive valuation with a 1.18 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -8.00%, its profits have risen by 38.3% ; the PEG ratio of the company is 0.3
4
Below par performance in long term as well as near term
- Along with generating -8.00% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Zeria Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zeria Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Zeria Pharmaceutical Co., Ltd.
-8.0%
0.17
20.01%
Japan Nikkei 225
36.73%
1.30
28.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.64%
EBIT Growth (5y)
24.92%
EBIT to Interest (avg)
21.87
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.62
Tax Ratio
21.01%
Dividend Payout Ratio
20.85%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.96%
ROE (avg)
8.64%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.22
EV to EBIT
10.39
EV to EBITDA
6.42
EV to Capital Employed
1.18
EV to Sales
1.45
PEG Ratio
0.28
Dividend Yield
NA
ROCE (Latest)
11.39%
ROE (Latest)
11.32%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at 17.44 %
INTEREST COVERAGE RATIO(Q)
Highest at 5,527.14
RAW MATERIAL COST(Y)
Fallen by 0.12% (YoY
NET SALES(Q)
Highest at JPY 24,116.29 MM
OPERATING PROFIT(Q)
Highest at JPY 6,792.36 MM
OPERATING PROFIT MARGIN(Q)
Highest at 28.17 %
PRE-TAX PROFIT(Q)
Highest at JPY 4,630.5 MM
NET PROFIT(Q)
Highest at JPY 3,816.48 MM
EPS(Q)
Highest at JPY 86.58
-10What is not working for the Company
NET PROFIT(9M)
At JPY 5,554.16 MM has Grown at -33.83%
INTEREST(HY)
At JPY 241.13 MM has Grown at 7.79%
ROCE(HY)
Lowest at 8.02%
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.27 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.21 times
Here's what is working for Zeria Pharmaceutical Co., Ltd.
Interest Coverage Ratio
Highest at 5,527.14
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Debt-Equity Ratio
Lowest at 17.44 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Net Sales
Highest at JPY 24,116.29 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 6,792.36 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 28.17 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 4,630.5 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Pre-Tax Profit
At JPY 4,630.5 MM has Grown at 71.02%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 3,816.48 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
Net Profit
At JPY 3,816.48 MM has Grown at 75.8%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 86.58
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Raw Material Cost
Fallen by 0.12% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Zeria Pharmaceutical Co., Ltd.
Interest
At JPY 241.13 MM has Grown at 7.79%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Inventory Turnover Ratio
Lowest at 1.27 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 3.21 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
